about
"Migraine side effect" and stroke recurrence in late follow-up after transcatheter patent foramen ovale closure as secondary prevention of cryptogenic thromboembolismAssessment of CHADS2 and CHA 2DS 2-VASc scores in obstructive sleep apnea patients with atrial fibrillation.Association of the CHADS2 and CHA 2DS 2-VASc scores with left atrial enlargement: a prospective cohort study of unselected atrial fibrillation patients.Presence and severity of obstructive sleep apnea and remote outcomes of atrial fibrillation ablations - a long-term prospective, cross-sectional cohort study.OSACS score-a new simple tool for identifying high risk for Obstructive Sleep Apnea Syndrome based on clinical parameters.Stroke Risk Factors Beyond the CHA₂DS₂-VASc Score: Can We Improve Our Identification of "High Stroke Risk" Patients With Atrial Fibrillation?Peripehral ARtery Atherosclerotic DIsease and SlEep disordered breathing (PARADISE) trial - protocol for an observational cohort study.Prevalence of depressive disorders in professional drivers - epidemiologic subanalysis of the RACER study.Assessment of cardiovascular risk in patients undergoing total joint alloplasty: the CRASH-JOINT study.Prevalence of Erectile Dysfunction in Atrial Fibrillation Patients: A Cross-Sectional, Epidemiological Study.Usefulness of the SAME-TT2R2 score to predict anticoagulation control on VKA in patients with atrial fibrillation and obstructive sleep apnea.Stratification of cardiovascular risk in patients with atrial fibrillation and obstructive sleep apnea-validity of the 2MACE score.Myocardial infarction type 4b in human immunodeficiency virus-infected patient.Substantial differences between human and ovine mesenchymal stem cells in response to osteogenic media: how to explain and how to manage?Author's reply: To PMID 25179885.Obstructive sleep apnoea in patients with atrial fibrillation: prevalence, determinants and clinical characteristics of patients in Polish population.Long QT interval in a patient after out-of-hospital cardiac arrest with hypocalcaemia, undergoing therapeutic hypothermia.[Should cardiologist routinely screen and evaluate patients for sleep disordered breathing?].Usefulness of the D-dimer concentration as a predictor of mortality in patients with out-of-hospital cardiac arrest.Seasonal trends in hypertension in Poland: evidence from Google search engine query data.Negative predictors of treatment success in outpatient therapy of arterial hypertension in Poland. Results of the CONTROL NT observational registry.Risk assessment according to the SCORE risk chart - from history, through present, to the future.Which components of the CHA2DS2-VASc score are the most important in obstructive sleep apnea patients with atrial fibrillation?Can continuous positive airway pressure therapy have antiarrhythmic properties?Sleep apnea and atrial fibrillation in coronary artery bypass grafting patients--also a part of the OSAFED syndrome?Is obstructive sleep apnea associated with the risk of ischemic stroke in patients with atrial fibrillation?Occurrence of poor sleep quality in atrial fibrillation patients according to the EHRA score.Sleep duration in the first months after ST elevation myocardial infarction: an independent predictor of all-cause mortality.Prognostic value of troponin I and NT-proBNP concentrations in patients after in-hospital cardiac arrest.Evaluation of the prevalence of periodontal disease, as a non-classical risk factor in the group of patients undergoing hip and/or knee arthroplasty.Epidemiology of dyslipidemia in professional drivers - results of RACER-ABPM (Risk of Adverse Cardiovascular Events among professional dRivers in Poland - Ambulatory Blood Pressure Monitoring) study.The use of an automated external defibrillator in a victim of car accident.Utilization of the lipid-lowering therapies in outpatient settings in Poland - epidemiological survey Economedica Dyslipidemia 2015.Prevalence of Hypertension in Professional Drivers (from the RACER-ABPM Study).Bioequivalence study of 2.5 mg film-coated bisoprolol tablets in healthy volunteers.Different ECG manifestations of left ventricular hypertrophy in presence of intermittent LBBB and RBBB.Clinical characteristics, aetiology and occurrence of type 2 acute myocardial infarction.Cardiovascular safety of novel non-small cell lung cancer oncotherapy in a patient treated with novel generations of tyrosine kinase inhibitors.Cardiac approach to a patient with breast cancer and metastases in musculoskeletal system.Atrial fibrillation as a first clinical manifestation of right atrial cavernous haemangioma.
P50
Q34613373-F116B3A1-72A9-48B4-A05B-8599C0E7B1AFQ35597696-624BFF49-913A-438B-88E8-6E1395419752Q35768680-60EC8E99-354D-4985-9419-0DB260184159Q36024079-AC4BD69A-1D2A-4705-B8BB-9A69F07B246FQ37680488-18231F3B-12CF-48BA-9579-2810BAD0BCDFQ38598690-7CF1FF9C-7BC7-4DF1-987F-41BAA68D91BCQ38675827-70F15F7A-1B0E-4187-AC27-41427A6C4844Q39185030-9AA54991-E845-4191-88D0-DD6E889BE6B0Q40460912-690940C6-9BED-4AC6-8D3E-C1F15477A9CCQ40493899-5DCD7C1D-8DCD-45B1-8B8F-B6B5F1780F56Q41048561-6B1BBDFD-214F-4A1A-AF5B-7CF99A167EF3Q41620649-69B729F0-EF91-4110-86DD-5F2ADB9D2771Q41896951-C99A3D77-8640-4542-B616-416C12A4AC93Q42185855-A94AD2B2-8A3C-4281-A95E-B01B17279CF7Q42318479-56A06540-07A9-4256-8543-03870095ED21Q43446634-B27C4CF3-FD6F-40C6-8D33-755FD70A2183Q43454044-CDE83816-BE0A-4FFA-90D9-23B49B8AC5E3Q43677392-F8F4721C-C8E8-40B0-B19D-5125599A043EQ44553766-8DB7DE82-95AC-4985-B4BD-46ABAE95259DQ47203230-1205D1F7-3902-4464-9183-833B529A8A08Q47608601-F8B0DC48-B620-468F-BFDB-E8D885C08300Q47843324-D56C9553-C39F-4C71-B8B9-7F1B654CB5DAQ47873164-A2AEE862-AAFE-4E50-AEEA-C9F34D80FB99Q47943893-8C2029AC-7465-4DBD-9EB0-802FE3440BDEQ47944815-EEB99184-73FD-4417-A04D-C3DD917106ABQ47989054-132CFD70-1AED-4D37-92EE-B72D07A31F25Q48070702-DD23D836-BB36-4DB4-9C89-2A9CB114ADC0Q48125841-24EBEE64-5E25-49A4-870D-163B6CF0904FQ48247882-AEDC8C30-74FA-440D-BDC6-E0FD5AD3AFB4Q49350051-532490DD-7834-4ABE-900B-915B10409CBAQ49382975-110B508D-8072-4D8D-95CD-7253EFAA5F99Q50048711-48B96687-BF55-4420-8E99-1C0887F30A8EQ50126705-6510649F-D633-4D52-BD78-816056C3A3BFQ50195912-E44A305D-8A4A-4CEC-8DCA-EF7FA1E16DBCQ50879003-F0A279BF-C5AA-4213-9DFA-436396893D7CQ51026260-1F2272A2-ED71-410B-994E-A355E8BBA59BQ51191711-A2A5EBE4-57B0-416A-B983-CC4E34975B84Q52646881-1EAFA190-7F52-4A66-8DE6-0684185AB332Q52879565-F092354C-349E-437D-ADD2-17499F1D9A9BQ53108173-69295844-6C1D-4B9E-8F4B-3A171EEA99F9
P50
description
Polish researcher
@en
polski naukowiec
@pl
taighdeoir Polannach
@ga
wetenschapper
@nl
name
Anna E Płatek
@ast
Anna E Płatek
@ca
Anna E Płatek
@de
Anna E Płatek
@en
Anna E Płatek
@es
Anna E Płatek
@fr
Anna E Płatek
@ga
Anna E Płatek
@gl
Anna E Płatek
@it
Anna E Płatek
@nl
type
label
Anna E Płatek
@ast
Anna E Płatek
@ca
Anna E Płatek
@de
Anna E Płatek
@en
Anna E Płatek
@es
Anna E Płatek
@fr
Anna E Płatek
@ga
Anna E Płatek
@gl
Anna E Płatek
@it
Anna E Płatek
@nl
altLabel
Anna E Platek
@en
prefLabel
Anna E Płatek
@ast
Anna E Płatek
@ca
Anna E Płatek
@de
Anna E Płatek
@en
Anna E Płatek
@es
Anna E Płatek
@fr
Anna E Płatek
@ga
Anna E Płatek
@gl
Anna E Płatek
@it
Anna E Płatek
@nl
P214
P1412
P1559
Anna E Płatek
@pl
P21
P214
P27
P31
P496
0000-0002-7286-2318
P735
P7859
viaf-313524953